Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mark Awad, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Mark Awad and Lynette Sholl.
Connection Strength

4.493
  1. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30.
    View in: PubMed
    Score: 0.663
  2. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187.
    View in: PubMed
    Score: 0.243
  3. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 06 24; 384(25):2382-2393.
    View in: PubMed
    Score: 0.242
  4. BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. JTO Clin Res Rep. 2021 Feb; 2(2):100127.
    View in: PubMed
    Score: 0.233
  5. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074.
    View in: PubMed
    Score: 0.227
  6. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814.
    View in: PubMed
    Score: 0.224
  7. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625.
    View in: PubMed
    Score: 0.220
  8. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 Oct; 30(10):1653-1659.
    View in: PubMed
    Score: 0.218
  9. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.217
  10. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659.
    View in: PubMed
    Score: 0.215
  11. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934.
    View in: PubMed
    Score: 0.211
  12. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102.
    View in: PubMed
    Score: 0.209
  13. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87.
    View in: PubMed
    Score: 0.207
  14. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. J Thorac Oncol. 2018 08; 13(8):e131-e133.
    View in: PubMed
    Score: 0.194
  15. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 2017 Nov 03; 8(54):92265-92274.
    View in: PubMed
    Score: 0.187
  16. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048.
    View in: PubMed
    Score: 0.176
  17. Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Cold Spring Harb Mol Case Stud. 2021 08; 7(4).
    View in: PubMed
    Score: 0.061
  18. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug; 11(8):1952-1969.
    View in: PubMed
    Score: 0.059
  19. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142.
    View in: PubMed
    Score: 0.056
  20. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology. 2019 10; 293(1):15-29.
    View in: PubMed
    Score: 0.053
  21. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 10 01; 29(10):2085-2091.
    View in: PubMed
    Score: 0.050
  22. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.050
  23. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5963-5976.
    View in: PubMed
    Score: 0.050
  24. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835.
    View in: PubMed
    Score: 0.049
  25. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunol Res. 2018 06; 6(6):630-635.
    View in: PubMed
    Score: 0.048
  26. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341.
    View in: PubMed
    Score: 0.044
  27. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016 09 08; 1(14):e89014.
    View in: PubMed
    Score: 0.043
  28. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.